The MAIA study was a phase 3 trial comparing lenalidomide and dexamethasone alone with daratumumab as an add-on therapy to lenalidomide and dexamethasone in patients with transplant-ineligible newly...
It is currently unclear how to best screen populations at risk for multiple myeloma and evaluate the potential effectiveness of early interventions. Using a computational model, researchers investigated...
An analysis of patient data from the Nurses’ Health Study, Health Professional Follow-Up Study and Women’s Health Study is leading researchers to make associations between age and modifiable risk factors...
The FDA has granted accelerated approval to linvoseltamab-gcpt, a BCMA-directed bispecific T-cell engager, offering a new option for patients with heavily pretreated relapsed or refractory multiple myeloma....
A new analysis from Western Washington investigators suggests that adverse financial events at diagnosis may delay treatment initiation for patients with hematologic malignancies, highlighting a potential...
